Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors

Cancer

Volumn 110, Issue 1, 2007, Pages 56-61

  D'Amico, Anthony V ^a   Chen, Ming Hui ^b   Catalona, William J ^c   Sun, Leon ^d   Roehl, Kimberly A ^e   Moul, Judd W ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

Mortality; Prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CAUSE OF DEATH; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; STATISTICAL ANALYSIS;

AGED; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS;

EID: 34250795026     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22737     Document Type: Article

References (19)

1. Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Freedland SJ. Changing nature of high risk patients undergoing radical prostatectomy. J Urol. 2007;177:113-117.
2. Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004: insights from national disease registries. Oncology. 2004;18: 1239-1247.
3. D'Amico AV, Chen MH, Roehl K, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
4. Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer. 2006;107:2597-2603.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per Milliliter. N Engl J Med. 2004; 350:2239-2246.
6. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66-70.
7. Greene FL. Prostate. In: Greene FL, Page DL, Fleming ID, Balch CM, Haller DG, Morrow M, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002:309-316.
8. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999;94: 496-509.
9. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88: 400-409.
10. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16: 1141-1154.
11. Neter J, Wassermann W, Kutner M, editors. Simultaneous inferences and other topics in regression analyses-1. In: Applied Linear Regression Models. Homewood, IL: Richard D. Irwin; 1983:150-153.
12. D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006;24: 4190-4195.
13. United States National Institutes of Health, Clinical Trials Website. Bethesda, MD: National Institutes of Health; 2005. Available at URL: http://clinicaltrials.gov/. Accessed May 7, 2007.
14. Tannock IF, de Wit R, Berry WR, et al. Tax 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
15. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
16. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
17. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447.
18. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-923.
19. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006;176: 868-874.